Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - adenosine, quantity: 3 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - therapeutic indications: rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory by-pass tracts (wolff-parkinson-white syndrome). diagnostic indications: aid to diagnosis of broad or narrow complex supraventricular tachycardias. although adenocor is not effective in converting atrial flutter, atrial fibrillation or ventricular tachycardia to sinus rhythm, the slowing of av conduction helps diagnosis of atrial activity. in this respect adenosine should be used as an adjunct to, but not a replacement for, clinical and ecg observations. it should be only used when, despite all diagnostic attempts, doubt still persists. improved diagnostic sensitivity of intracavity electrophysiological investigations

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - adenosine 3 mg/ml (candida utilis lysed to get rna,then hydrolysed to adenosine);   - solution for injection - 6 mg/2ml - active: adenosine 3 mg/ml (candida utilis lysed to get rna,then hydrolysed to adenosine)   excipient: sodium chloride water for injection - adenocor is indicated for rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (wolff-parkinson-white syndrome), and as an aid to diagnosis of broad or narrow qrs complex supraventricular tachycardias, and in sensitisation of intracavity electrophysiological investigations.

Israel - English - Ministry of Health

sanofi - aventis israel ltd - adenosine - solution for injection - adenosine 6 mg / 2 ml - adenosine - adenosine - rapid conversion to a normal sinus rhythm of paroxysmal supraventicular tachycardias including those associated with accessory bypass tracts (wolf parkinson-white syndrome).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - adenosine -

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - adenosine - injection - 6.0mg/2 ml - adenosine 6.0mg/2 ml

Malta - English - Medicines Authority

sanofi malta limited level2, fort business centre, mriehel bypass, birkirkara, malta - adenosine - solution for injection - adenosine 3 mg/ml - cardiac therapy

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - adenosine - solution for injection - 3mg/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - adenosine - solution for injection - 3 milligram(s)/millilitre - other cardiac preparations; adenosine

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - adenosine -